iRadimed reports Q3 adjusted EPS 43c vs 43c last year

Reports Q3 revenue $18.33M vs $16.505M last year. “I am pleased to announce another record-breaking quarter, marking our thirteenth consecutive quarter of record revenue. Our domestic IV infusion pump revenue remained exceptionally strong, driving our quarter’s performance as we exceeded our guidance on both revenue and EPS, supported by continued strength in our gross margins. We remain confident that the momentum in our bookings will carry into the fourth quarter, positioning us for continued success as we close out the year,” said Roger Susi, President and Chief Executive Officer of the Company.